Ovid Therapeutics announces CEO transition effective January 2026

New York, November 12, 2025 (Globe Newswire) -- Ovid Therapeutics unveiled a CEO succession plan in which Meg Alexander will become Chief Executive Officer and join the Board on January 1, 2026, while co-founder Dr. Jeremy Levin shifts to Executive Chairman. The announcement accompanied the company’s third-quarter 2025 financial results and updates on its pipeline progress. Alexander, who has played a key role in shaping the company’s strategy and operations since 2021, will work closely with Dr. Levin during the transition to ensure continuity.

Read article here.